RT-GLP3 peptide for research applications
GLP-3 peptide for research applications

RT-GLP3

Price range: $150.00 through $200.00

Choose between either 18mg or 30mg reagent-grade GLP-3.

Third Party Verified

30 MG 03/26/2026

16 MG – RG15608J – 07/22/2025

16 MG – RG15608J – 07/22/2025 – Endotoxin

Please select product options above to see quantity discounts
SKU: RT-GLP3-18MG Category:

Description

RT-GLP3 (LY3437943)

Reagent-Grade Research Compound  |  SKU: RT-GLP3-18MG / RT-GLP3-30MG

NOTICE: This product is sold exclusively as a reagent-grade research compound for in-vitro laboratory, analytical, and scientific investigation purposes. It is not approved by the FDA for any clinical, therapeutic, diagnostic, or veterinary application. Not for human consumption.

 

Product Specifications

Parameter Value
Catalog Name RT-GLP3
Category Synthetic peptide; triple incretin receptor ligand (research designation)
CAS Number 2381089-83-2
Molecular Formula C₁₈₇H₂₉₁N₄₅O₅₉
Molecular Weight ~4,276.6 g/mol
Sequence Length 31 amino acids
Form Lyophilized powder
Purity ≥95% (HPLC-verified)
Appearance White to off-white lyophilized powder
Solubility Soluble in sterile water, PBS, or dilute acetic acid
Available Sizes 18 mg, 30 mg

 

Storage & Handling

Condition Recommendation
Lyophilized Store at −20°C, protected from light and moisture
Reconstituted Aliquot and store at −80°C; minimize freeze-thaw cycles
Shelf Life 24 months from date of manufacture (lyophilized, sealed)

 

Amino Acid Sequence

H-Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Leu(Me)-Lys(AEEA-γGlu-C20-diacid)-Ala-Gln-Ala-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂

 

Structural Modifications

Modification Description
Aib (Position 2) 2-Aminoisobutyric acid; confers resistance to DPP-4 enzymatic cleavage
Leu(Me) (Position 13) α-Methyl-L-leucine; enhances peptide backbone stability
Lys conjugation (Pos. 14) C20 fatty diacid via γ-glutamic acid and AEEA linker; facilitates albumin binding in serum
C-terminal amidation Ser-NH₂; standard modification for peptide stability

 

Receptor Binding Profile

RT-GLP3 has been characterized in published literature as a ligand for the following class B GPCRs:

Receptor Target Abbreviation Signaling Pathway
Glucose-dependent Insulinotropic Polypeptide Receptor GIPR cAMP / PKA
Glucagon-Like Peptide-1 Receptor GLP-1R cAMP / PKA
Glucagon Receptor GCGR cAMP / PKA / EPAC

 

Quality Documentation

Each batch is accompanied by a Certificate of Analysis (CoA) including:

  • HPLC purity analysis (≥95%)
  • Mass spectrometry confirmation (molecular weight verification)
  • Endotoxin testing (LAL method)
  • Independent third-party verification (Janoshik Analytical)

Current batch documentation:

Size Batch Test Date Verification
30 mg 03/26/2026 03/26/2026 CoA on file
16 mg RG15608J 07/22/2025 Janoshik #70933

 

Published Literature

The following peer-reviewed publications describe investigations involving this compound. Citations are provided for researcher reference only and do not constitute endorsement of any application.

  1. Li W, Zhou Q, Cong Z, et al. Structural insights into the triple agonism at GLP-1R, GIPR, and GCGR manifested by retatrutide. Cell Discovery. 2024;10(1):77. doi:10.1038/s41421-024-00700-0
  2. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. doi:10.1056/NEJMoa2301972
  3. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes. Lancet. 2022;400(10366):1869–1881. doi:10.1016/S0140-6736(22)02033-5
  4. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for MASLD: a randomized phase 2a trial. Nature Medicine. 2024;30(7):2037–2048. doi:10.1038/s41591-024-03018-2
  5. Kopp KO, Li Y, Glotfelty EJ, et al. Incretin-Based Multi-Agonist Peptides in Cellular Models of Neurodegeneration. Biomolecules. 2024;14(7):872. doi:10.3390/biom14070872

 

Regulatory & Compliance Statement

This product is intended exclusively for in-vitro research, laboratory testing, and analytical applications. It is not intended for use in humans, animals, food products, cosmetics, or any clinical/diagnostic application. Peptide Minds (operated by Accelairate LLC) is a chemical reagent supplier. It is not a compounding pharmacy under Section 503A, nor an outsourcing facility under Section 503B, of the Federal Food, Drug, and Cosmetic Act. Products have not been evaluated by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. By purchasing this product, the buyer represents that they are at least 21 years of age and that the product will be used solely for lawful research purposes by qualified personnel in compliance with all applicable regulations.

 

Additional information

Size

18mg, 30mg

Reviews

There are no reviews yet.

Be the first to review “RT-GLP3”

Your email address will not be published. Required fields are marked *

Related products

Premium research-grade peptides for laboratory use only. Third-party tested. GMP-compliant manufacturing. Strictly for in vitro research and analytical applications.

Quick Links

Legal Pages

Our Newsletter

All products on this site are sold only as research chemicals. Products are offered for in vitro research, laboratory testing & analytical purposes only. Products are not to be used in any human or animal application.

Peptide Minds is a chemical supplier. Peptide Minds is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. Peptide Minds is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.

The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.